Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
Sponsor
University of Sao Paulo (Other)
Overall Status
Unknown status
CT.gov ID
NCT01072058
Collaborator
(none)
100
1
1
Study Details
Study Description
Brief Summary
The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
Study Start Date
:
Feb 1, 2008
Actual Primary Completion Date
:
Feb 1, 2011
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: TNF blockers
|
Drug: TNF blockers (infliximab, adalimumab, etanercept)
Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
|
Outcome Measures
Primary Outcome Measures
- Development, deterioration ou improvement of subclinical heart dysfunction [0, 6 ,12, 18 and 24 months]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers
-
Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers
Exclusion Criteria:
-
Clinical heart failure
-
Chagas'disease
-
Stable or unstable angina
-
Past history of myocardial infarct
-
Systemic árterial hypertension (grade 3)
-
Valvulopathy
-
Chronic kidney disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de são PAulo | Sao Paulo | Brazil |
Sponsors and Collaborators
- University of Sao Paulo
Investigators
- Study Director: Eloisa S.D.O. Bonfá, MD, PhD,
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Julio Moraes, MD,
MD,
University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT01072058
Other Study ID Numbers:
- CapPesq1252/07
First Posted:
Feb 19, 2010
Last Update Posted:
Jun 7, 2013
Last Verified:
Jun 1, 2013
Keywords provided by Julio Moraes, MD,
MD,
University of Sao Paulo
Additional relevant MeSH terms: